
Industry-sponsored clinical drug trials in Egypt
Ethical questions in a challenging context

When engaging in clinical trials in low- and middle-income countries with limited access to treatment, pharmaceutical companies should ascertain that the safety and rights of participants are properly protected and that their practice are in line with the highest ethical standards. They should also make sure that the medications tested in those countries are available at an affordable price. This study brings new evidence that unethical practices occur in TNC sponsored clinical trials conducted in Egypt, and that drugs tested in Egypt are not systematically available to and mostly unaffordable for the Egyptian population.
Do you need more information?
-
Irene Schipper
Senior Researcher
Partners
Publication

Related news
-
-
Big Pharma raked in USD 90 billion in profits with COVID-19 vaccinesPosted in category:NewsEsther de HaanPublished on:
-
Pharma’s pandemic profits Published on:Esther de HaanPosted in category:PublicationEsther de Haan